Anti-tumor activity of the proteasome inhibitor bortezomib in gastric cancer

International Journal of Oncology

Volumn 39, Issue 6, 2011, Pages 1529-1536

  Nakata, Wachiko ^a   Hayakawa, Yoku ^a   Nakagawa, Hayato ^a   Sakamoto, Kei ^b   Kinoshita, Hiroto ^a   Takahashi, Ryota ^a   Hirata, Yoshihiro ^a   Maeda, Shin ^a,c   Koike, Kazuhiko ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b INSTITUTE FOR ADULT DISEASES   (Japan)

^c YOKOHAMA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Bortezomib; Molecular targeting therapy; NF B; Proteasome inhibitor; Stomach neoplasms

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; ANTIMITOTIC AGENT; BORTEZOMIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; REACTIVE OXYGEN METABOLITE; STRESS ACTIVATED PROTEIN KINASE;

ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CELL SURVIVAL; CONTROLLED STUDY; DRUG EFFECT; IN VITRO SELECTION; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; STOMACH CANCER;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BORONIC ACIDS; CELL PROLIFERATION; HUMANS; MALE; MAP KINASE KINASE 4; MICE; MICE, INBRED BALB C; MICE, NUDE; NF-KAPPA B; PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION; STOMACH NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 80054823353     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2011.1141     Document Type: Article

References (21)

1. Maruyama K, Kaminishi M, Hayashi K, Isobe Y, Honda I, Katai H, Arai K, Kodera Y and Nashimoto A: Gastric cancer treated in 1991 in Japan: data analysis of nationwide registry. Gastric Cancer 9: 51-66, 2006. (Pubitemid 43890701)
2. Tabernero J, Van Cutsem E, Diaz-Rubio E, Cervantes A, Humblet Y, Andre T, Van Laethem JL, Soulie P, Casado E, Verslype C, Valera JS, Tortora G, Ciardiello F, Kisker O and de Gramont A: Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 25: 5225-5232, 2007. (Pubitemid 350232254)
3. Kabbinavar FF, Hambleton J, Mass RD, Hurwitz HI, Bergsland E and Sarkar S: Combined analysis of efficacy: the addition of beva cizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol 23: 3706-3712, 2005.
4. Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, Goldschmidt H, Reece D, San-Miguel JF, Blade J, Boccadoro M, Cavenagh J, Dalton WS, Boral AL, Esseltine DL, Porter JB, Schenkein D and Anderson KC: Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 352: 2487-2498, 2005. (Pubitemid 41007864)
5. San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, Spicka I, Petrucci MT, Palumbo A, Samoilova OS, Dmoszynska A, Abdulkadyrov KM, Schots R, Jiang B, Mateos MV, Anderson KC, Esseltine DL, Liu K, Cakana A, van de Velde H and Richardson PG: Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 359: 906-917, 2008.
6. Fujita T, Doihara H, Washio K, Ino H, Murakami M, Naito M and Shimizu N: Antitumor effects and drug interactions of the proteasome inhibitor bortezomib (PS341) in gastric cancer cells. Anticancer Drugs 18: 677-686, 2007. (Pubitemid 47343660)
7. Bae SH, Ryoo HM, Kim MK, Lee KH, Sin JI and Hyun MS: Effects of the proteasome inhibitor bortezomib alone and in combination with chemotherapeutic agents in gastric cancer cell lines. Oncol Rep 19: 1027-1032, 2008. (Pubitemid 351802676)
8. Nawrocki ST, Sweeney-Gotsch B, Takamori R and McConkey DJ: The proteasome inhibitor bortezomib enhances the activity of docetaxel in orthotopic human pancreatic tumor xenografts. Mol Cancer Ther 3: 59-70, 2004. (Pubitemid 39193679)
9. Williams S, Pettaway C, Song R, Papandreou C, Logothetis C and McConkey DJ: Differential effects of the proteasome inhibitor bortezomib on apoptosis and angiogenesis in human prostate tumor xenografts. Mol Cancer Ther 2: 835-843, 2003.
10. Hideshima T, Richardson P, Chauhan D, Palombella VJ, Elliott PJ, Adams J and Anderson KC: The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 61: 3071-3076, 2001. (Pubitemid 32691956)
11. LeBlanc R, Catley LP, Hideshima T, Lentzsch S, Mitsiades CS, Mitsiades N, Neuberg D, Goloubeva O, Pien CS, Adams J, Gupta D, Richardson PG, Munshi NC and Anderson KC: Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res 62: 4996-5000, 2002. (Pubitemid 34984425)
12. Yu C, Rahmani M, Dent P and Grant S: The hierarchical relationship between MAPK signaling and ROS generation in human leukemia cells undergoing apoptosis in response to the proteasome inhibitor Bortezomib. Exp Cell Res 295: 555-566, 2004. (Pubitemid 38490507)
13. Small GW, Shi YY, Edmund NA, Somasundaram S, Moore DT and Orlowski RZ: Evidence that mitogen-activated protein kinase phosphatase-1 induction by proteasome inhibitors plays an antiapoptotic role. Mol Pharmacol 66: 1478-1490, 2004. (Pubitemid 39564774)
14. Chen KF, Yeh PY, Yeh KH, Lu YS, Huang SY and Cheng AL: Down-regulation of phospho-Akt is a major molecular determinant of bortezomib-induced apoptosis in hepatocellular carcinoma cells. Cancer Res 68: 6698-6707, 2008.
15. Kamata H, Honda S, Maeda S, Chang L, Hirata H and Karin M: Reactive oxygen species promote TNFalpha-induced death and sustained JNK activation by inhibiting MAP kinase phosphatases. Cell 120: 649-661, 2005. (Pubitemid 40343077)
16. Sakon S, Xue X, Takekawa M, Sasazuki T, Okazaki T, Kojima Y, Piao JH, Yagita H, Okumura K, Doi T and Nakano H: NF-kappaB inhibits TNF-induced accumulation of ROS that mediate prolonged MAPK activation and necrotic cell death. EMBO J 22: 3898-3909, 2003. (Pubitemid 36975716)
17. Dasmahapatra G, Rahmani M, Dent P and Grant S: The tyrphostin adaphostin interacts synergistically with proteasome inhibitors to induce apoptosis in human leukemia cells through a reactive oxygen species (ROS)-dependent mechanism. Blood 107: 232-240, 2006. (Pubitemid 43053548)
18. Bazzaro M, Lee MK, Zoso A, Stirling WL, Santillan A, Shih IeM and Roden RB: Ubiquitin-proteasome system stress sensitizes ovarian cancer to proteasome inhibitor-induced apoptosis. Cancer Res 66: 3754-3763, 2006.
19. Jatoi A, Dakhil SR, Foster NR, Ma C, Rowland KM Jr, Moore DF Jr, Jaslowski AJ, Thomas SP, Hauge MD, Flynn PJ, Stella PJ and Alberts SR: Bortezomib, paclitaxel, and carboplatin as a first-line regimen for patients with metastatic esophageal, gastric, and gastroesophageal cancer: phase II results from the North Central Cancer Treatment Group (N044B). J Thorac Oncol 3: 516-520, 2008. (Pubitemid 351630280)
20. Shah MA, Power DG, Kindler HL, Holen KD, Kemeny MM, Ilson DH, Tang L, Capanu M, Wright JJ and Kelsen DP: A multicenter, phase II study of Bortezomib (PS-341) in patients with unresectable or metastatic gastric and gastroesophageal junction adenocarcinoma. Invest New Drugs (In press).
21. Fujihara T, Sawada T, Hirakawa K, Chung YS, Yashiro M, Inoue T and Sowa M: Establishment of lymph node metastatic model for human gastric cancer in nude mice and analysis of factors associated with metastasis. Clin Exp Metastasis 16: 389-398, 1998. (Pubitemid 28255534)